NCT06580106Recruiting
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
A Prospective Pilot Study of the Genetic Determinants of Toxicity and Response to Azacitidine and Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Through Evaluation of Polymorphisms in Pharmacokinetic Genes and Venetoclax Levels
Source: ClinicalTrials.gov · Last updated 24 Jul 2026
Brief summary (registry, in English)
The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 14 Aug 2024
- Start date
- 9 Apr 2025
- Primary completion date
- Jul 2027
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT06580106
What you commit to
- Study type: Observational
- Planned participants: 50
- From 9 Apr 2025 to the primary completion date, Jul 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Written informed consent and HIPAA authorization for release of personal health information.
- Age ≥ 18 years of age at the time of consent
- Confirmed diagnosis of AML
- Planned initial treatment with azacitidine and venetoclax
- Ability to read and understand the English and/or Spanish language
- As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Levine Cancer Institute Coordinator of this site? Confirm its status | Charlotte | United States | Recruiting |
| Wake Forest Baptist Comprehensive Cancer Center Coordinator of this site? Confirm its status | Winston-Salem | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.